Serum Metabolic Profiling in a Mouse Model of Adriamycin-lnduced Focal Segmental Glomerulosclerosis
Serum Metabolic Profiling in a Mouse Model of Adriamycin-lnduced Focal Segmental Glomerulosclerosis
复制标题
DOI：
10.4103/0366-6999.245266
复制
发表时间：
2018
影响因子：
6.1
通讯作者：
Hu Zhao
中科院分区：
文献类型：
--
作者：
Lyu Li;Wang Caili;Li Zengyan;Shi Yingjin;Zhang Yanhui;Mi Yan;Hu Zhao
To the Editor: Focal segmental glomerulosclerosis (FSGS) is one of the leading causes of end-stage kidney disease. However, no ideal intervention prevents FSGS progression due to the unclear physiopathological mechanisms. Adriamycin (ADR)-induced FSGS is a well-accepted model that mimics human FSGS. ADR, a common chemotherapeutic agent associated with nephrotoxicity, causes kidney damage by triggering imbalances between free oxygen radicals and antioxidant enzymes; however, the precise mechanisms of ADR-induced FSGS are not completely clear. Metabolomics analysis is thought to be promising for monitoring treatment responses, making diagnoses, and tracking pathogenesis of diseases by assessing the end products of cellular processes and providing a nonbiased identification and quantification of all metabolites in a bioinformatics platform. In the present study, we aimed to investigate serum metabolomic variations of ADR-induced FSGS model using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS/MS) data collection technique. Here, we described the method of generating FSGS model using BALB/c mice in our laboratory. The clinical feature of ADR-induced FSGS was assessed by an increase in proteinuria, a rise in serum creatinine (SCR) and a loss of body weight. Serum and organs were harvested at 4 weeks after ADR administration, to assess kidney function, kidney pathological changes as well as serum metabolomic variations.
